Zevra Therapeutics annual operating margin
2019
2020
2021
2022
2023
2024
2025
Zevra Therapeutics's operating margin was −59.12% for fiscal 2025.
View full Zevra Therapeutics company overview| Fiscal year | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −59.12% | +309.35 pp |
| 2024 | 2024-12-31 | −368.47% | −187.84 pp |
| 2023 | 2023-12-31 | −180.63% | +238.27 pp |
| 2022 | 2022-12-31 | −418.91% | −445.88 pp |
| 2021 | 2021-12-31 | 26.98% | +69.19 pp |
| 2020 | 2020-12-31 | −42.21% | +116.19 pp |
| 2019 | 2019-12-31 | −158.40% | — |
| Fiscal quarter | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | 42.30% | +316.78 pp |
| Q1 2026 | 2026-03-31 | 143.97% | +170.25 pp |
| Q4 2025 | 2025-12-31 | 27.30% | +155.30 pp |
| Q3 2025 | 2025-09-30 | 15.90% | +754.89 pp |
| Q2 2025 | 2025-06-30 | −274.48% | +260.36 pp |
| Q1 2025 | 2025-03-31 | −26.28% | +571.85 pp |
| Q4 2024 | 2024-12-31 | −128.01% | −10.69 pp |
| Q3 2024 | 2024-09-30 | −739.00% | −208.29 pp |
| Q2 2024 | 2024-06-30 | −534.84% | −461.03 pp |
| Q1 2024 | 2024-03-31 | −598.13% | −194.13 pp |
| Q4 2023 | 2023-12-31 | −117.31% | +343.27 pp |
| Q3 2023 | 2023-09-30 | −530.71% | −300.16 pp |
| Q2 2023 | 2023-06-30 | −73.81% | +1831.34 pp |
| Q1 2023 | 2023-03-31 | −404.00% | −357.11 pp |
| Q4 2022 | 2022-12-31 | −460.58% | −350.51 pp |
| Q3 2022 | 2022-09-30 | −230.55% | −117.47 pp |
| Q2 2022 | 2022-06-30 | −1,905.15% | −1953.82 pp |
| Q1 2022 | 2022-03-31 | −46.89% | −104.33 pp |
| Q4 2021 | 2021-12-31 | −110.07% | +25.77 pp |
| Q3 2021 | 2021-09-30 | −113.08% | −50.07 pp |
| Q2 2021 | 2021-06-30 | 48.67% | +11.13 pp |
| Q1 2021 | 2021-03-31 | 57.44% | +238.15 pp |
| Q4 2020 | 2020-12-31 | −135.84% | −164.05 pp |
| Q3 2020 | 2020-09-30 | −63.01% | — |
| Q2 2020 | 2020-06-30 | 37.54% | — |
| Q1 2020 | 2020-03-31 | −180.71% | — |
| Q3 2019 | 2019-09-30 | 28.21% | — |
Over the last five reported fiscal years, Zevra Therapeutics's operating margin decreased from −42.21% to −59.12%, a change of −16.91 percentage points. The latest reported quarter, Q2 2026, shows 42.30%.
Operating margin measures the percentage of revenue left after operating costs and expenses. It shows how much operating profit a company generates from each dollar of revenue.
TickerStat calculates operating margin as SEC-reported operating income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Zevra Therapeutics filings at SEC.gov ↗